Skip to content

The Pediatric Antiretroviral Pipeline

By Polly Clayden NOTE: a postscript section at the end of this article includes periodic updates since publication in June 2012. In the past year—since our last Pipeline Report—there has been a flurry of activity in pediatric antiretroviral drug development…

Read more

The Antiretroviral Pipeline

July 2012 By Simon Collins NOTE: a postscript section at the end of this article includes periodic updates since publication in June 2012. Updates from CROI 2013. (March 2013) at the end of this article. INTRODUCTION Two aspects of antiretroviral…

Read more

Introduction and Executive Summary

July 2012 By Polly Clayden and Mark Harrington In nine countries, we enrolled 1763 couples in which one partner was HIV-1–positive and the other was HIV-1–negative; 54% of the subjects were from Africa, and 50% of infected partners were men.…

Read more

The Tuberculosis Treatment Pipeline for Children

July 2018 by Lindsay McKenna Pharmacokinetic (PK) and safety studies in children continue to progress, producing a steady flow of data (Table 2). Yet the translation of research and development gains into policy and access for children with tuberculosis (TB)…

Read more

The Tuberculosis Prevention Pipeline for Children

July 2018 by Lindsay McKenna Tuberculosis (TB) prevention research is advancing (see The Tuberculosis Prevention Pipeline), yet the inclusion of children in these studies to ensure they benefit from such advances is inconsistent. Promisingly, studies to evaluate the use of…

Read more

The Tuberculosis Diagnosis Pipeline for Children

July 2018 by Lindsay McKenna Existing tests and those under development that are designed to detect tuberculosis (TB) bacteria (see the Tuberculosis Diagnosis Pipeline, coming soon) are suboptimal for children, who often have fewer TB bacteria in their bodies than…

Read more
Back To Top